K-Bio grows up: South Korea's biotech sector must now prove it can generate cash

In a sector analysis report titled "The New K-BIO", published on 18th August 2026, Kiwoom Securities argued that South Korea's biotechnology sector must transition away from a model driven by technology licensing announcements towards one that proves its ability to generate real, sustained cash flows. The brokerage issued Buy ratings on Yuhan Corporation (target price: KRW 110,000), Celltrion (target price: KRW 250,000), and HanAll Biopharma (target price: KRW 80,000), and named OliX Pharmaceuticals as its top pick among biotechnology stocks on its watchlist.

Heo Hye-min, the analyst at Kiwoom Securities Research Centre who authored the report, observed that the domestic pharmaceutical and biotech market has long followed a boom-and-bust cycle: excitement builds around technology licensing deals and clinical trial milestones, only to be punctured by failures and contract terminations. "What the sector now needs," she wrote, "is not more events, but a credible demonstration that those expectations can translate into genuine value." A cluster of setbacks in the first half of 2026—uncertainty surrounding Kolon TissueGene and HLB's global Phase 3 trials, Alteogen's disclosure of its royalty rate, and the apparent downgrading of ABL Bio's out-licensed drug within its big-pharma partner's development priorities—has, in her view, served as a useful lesson for the market.

The report grounds its case for a reframing of K-bio investment in an American historical precedent. In the early 2010s, a succession of commercial breakthroughs—Gilead's Sovaldi, Biogen's Tecfidera, Regeneron's Eylea—drove the Nasdaq Biotechnology Index (NBI) up by 394% between 2010 and July 2015. The key insight, the report argues, was not that any single company succeeded, but that as more and more biotechs began generating real profits, investors gradually came to trust the sector's underlying business model. The resulting re-rating of the entire sector was the consequence.

Kiwoom Securities contends that South Korea is approaching a comparable turning point. Alteogen's subcutaneous formulation of Keytruda, marketed as Keytruda Qlex and based on the company's ALT-B4 drug delivery platform, received FDA approval in September 2025 and went on sale the same month. After being assigned a J-Code (a billing classification used by American insurers) in April 2026, the product recorded second-quarter sales of USD 463m—a 262% jump from the preceding quarter. The share of Keytruda patients switching to the subcutaneous formulation rose from 1.6% in the first quarter to 5.5% in the second. MSD, which markets the drug, has projected that the conversion rate will reach 30–40% within the next 12 to 18 months.

Lazertinib, the lung cancer drug developed by Yuhan Corporation and Oscotec and licensed to Johnson & Johnson, was approved in the United States in August 2024 under the brand name Lazcluze and is now on sale. The report describes it as a commercialisation milestone achieved six years after the original licensing agreement. Yet the analysis is candid about the drug's sluggish early uptake: second-quarter US prescription revenues stood at roughly USD 30m, well below what the market had anticipated relative to the rival drug Tagrisso. "If market penetration remains limited in the second half of this year," the report cautions, "it will be necessary to examine whether the issue goes beyond a routine launch ramp-up, and whether physicians are in fact placing greater weight on Tagrisso's convenience and safety profile than on Lazcluze's improvement in overall survival—a structural rather than a temporary constraint."

The royalty revenues flowing from these two products remain modest. Kiwoom Securities estimates that total royalty income from South Korea's major out-licensed drugs amounted to only approximately KRW 14bn in 2025. The figure is expected to reach KRW 30–40bn in 2026 before potentially accelerating to KRW 70–140bn in 2027, depending on market penetration, and expanding further to several hundred billion won after 2029.

The report's recommended investment strategy is to focus on companies that combine cash-flow visibility with genuine growth prospects. Yuhan Corporation is the brokerage's top pick, supported by the expanding prescription base for Lazcluze and a growing pipeline of high-margin active pharmaceutical ingredient orders at its subsidiary Yuhan Chemical, which signed a supply contract worth KRW 210.2bn with Gilead Sciences in May 2026. Celltrion's key near-term catalysts are identified as the planned US launch of Omrizur—its biosimilar version of Xolair (omalizumab)—in the second half of the year (the product achieved KRW 99.3bn in European sales in 2025), and the expansion of Zymfentra's approved indications to include rheumatoid arthritis. HanAll Biopharma, newly initiated at Buy with a target price of KRW 80,000, is viewed as approaching the point at which clinical readouts for Graves' disease and myasthenia gravis—both expected in 2027—could provide meaningful evidence of commercial viability.

The report's projections, however, rest on assumptions that merit scrutiny. The royalty estimates for later-stage pipeline drugs presuppose that each of several individual clinical programmes succeeds: they include FDA approval of ABL Bio's bile duct cancer treatment and a successful Phase 3 outcome for Aribio's Alzheimer's drug. Alzheimer's disease is a therapeutic area with a long global history of late-stage trial failures, and ABL Bio's bile duct cancer drug, tovecimig, failed to achieve statistical significance on its secondary endpoint of overall survival—leaving open the critical question of whether the FDA will accept the existing data as sufficient grounds for approval.

The report also calls for a more rigorous assessment of the quality of technology licensing deals. "Contract signings alone are no longer enough," it argues. "Investors should examine upfront payments, near-term milestones, royalty rates, and the seriousness of the partner's development commitment." The data presented are striking: since 2015, upfront payments on South Korean out-licensing deals have averaged just 4.2% of headline contract values, meaning the gap between the cash actually received at signing and the total deal size announced to the market is often very wide.

One signal the report flags with cautious interest is growing investment in K-bio stocks by global asset managers. As of August 2026, BlackRock held a 6.5% stake in Yuhan Corporation and a 5.03% stake in Alteogen. Yet the report is careful not to overstate the significance of these positions, noting that BlackRock manages large passive and index-tracking funds, and that some of these holdings may reflect index rebalancing rather than active conviction in South Korea's biotechnology sector. Drawing firm conclusions about broad foreign institutional enthusiasm, it concludes, would be premature.